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Chronic lymphocytic leukemia (CLL) is a heterogeneous
B-cell cancer exhibiting a wide spectrum of disease
courses and treatment responses. Molecular character-
ization of RNA and DNA from CLL cases has led to the
identification of important driver mutations and disease
subtypes, but the precise mechanisms of disease pro-
gression remain elusive. To further our understanding of
CLL biology we performed isobaric labeling and mass
spectrometry proteomics on 14 CLL samples, comparing
them with B-cells from healthy donors (HDB). Of 8694
identified proteins, 6000 were relatively quantitated be-
tween all samples (q<0.01). A clear CLL signature, inde-
pendent of subtype, of 544 significantly overexpressed
proteins relative to HDB was identified, highlighting es-
tablished hallmarks of CLL (e.g. CD5, BCL2, ROR1 and
CD23 overexpression). Previously unrecognized surface
markers demonstrated overexpression (e.g. CKAP4,
PIGR, TMCC3 and CD75) and three of these (LAX1,
CLEC17A and ATP2B4) were implicated in B-cell receptor
signaling, which plays an important role in CLL pathogen-
esis. Several other proteins (e.g.Wee1, HMOX1/2, HDAC7
and INPP5F) were identified with significant overexpres-
sion that also represent potential targets. Western blot-
ting confirmed overexpression of a selection of these
proteins in an independent cohort. mRNA processing
machinery were broadly upregulated across the CLL
samples. Spliceosome components demonstrated con-
sistent overexpression (p  1.3  1021) suggesting
dysregulation in CLL, independent of SF3B1 mutations.
This study highlights the potential of proteomics in the
identification of putative CLL therapeutic targets and
reveals a subtype-independent protein expression sig-
nature in CLL. Molecular & Cellular Proteomics 17:
10.1074/mcp.RA117.000539, 776–791, 2018.
Chronic lymphocytic leukemia (CLL)1, the most common
adult leukemia in the western world, is a CD5 B-cell neo-
plasm with a heterogeneous clinical course (1, 2). B-cell re-
ceptor (BCR) signaling plays a role in the pathogenesis of
CLL, and drugs targeting this pathway are revolutionizing CLL
treatment (3). Indeed, the mutational status of the immuno-
globulin heavy-chain variable-region gene (IGHV) within the
BCR largely correlates with disease outcome. CLL cases with
unmutated V-genes (U-CLL) typically have a progressive dis-
ease with patients often requiring early treatment, in contrast
cases with mutated V-genes (M-CLL) are more indolent, and
those presenting with a low tumor burden often never require
treatment (4).
CLL transcriptomics analyses have identified minimal dif-
ferences in gene expression between subtypes such as U-
and M-CLL suggesting that common mechanisms elicit CLL
From the ‡Antibody and Vaccine Group, Cancer Sciences Unit,
Faculty of Medicine, General Hospital, University of Southampton,
Southampton, UK; §Centre for Proteomic Research, Institute for Life
Sciences, University of Southampton, Highfield Campus, Southamp-
ton, UK; ¶Cancer Genomics, Cancer Sciences Unit, Faculty of Med-
icine, University of Southampton, Southampton, UK.; Cancer
Sciences Unit, Faculty of Medicine, University of Southampton,
Southampton, UK; **Clinical and Experimental Sciences Unit, Faculty
of Medicine, University of Southampton, Southampton, UK; ‡‡De-
partment of Molecular Pathology, Royal Bournemouth Hospital, Bour-
nemouth, UK; §§Leukemia and Lymphoma Molecular Mechanisms
and Therapy Group, Cancer Sciences Unit, Faculty of Medicine,
University of Southampton, Southampton, UK; ¶¶Department of
Haematology, Royal Bournemouth Hospital, Bournemouth, UK
Received December 14, 2017
Published, MCP Papers in Press, January 24, 2018, DOI 10.1074/
mcp.RA117.000539
Author contributions: H.E.J., M.L., D.O., J.C.S., A.J.S., R.W., and
M.S.C. designed research; H.E.J. and M.J.C. performed research;
H.E.J., J.C., and M.S.C. analyzed data; H.E.J., M.J.C., D.O., J.C.S.,
A.J.S., R.W., and M.S.C. wrote the paper; S.D.G. and R.W. contrib-
uted new reagents/analytic tools.
1 The abbreviations used are: CLL, Chronic lymphocytic leukaemia;
HDB, Healthy donor B-cells; IGHV, Immunoglobulin heavy-chain vari-
able-region gene; MBC, Memory B-cells; M-CLL, IGHV-mutated CLL;
NBC, Naive B cells; NOTCH1, Neurogenic locus notch homolog
protein 1; PBMCs, Peripheral blood mononuclear cells; Rs, Regula-
tion score; SF3B1, Splicing factor 3B subunit 1; TMT, Tandem mass
tags; Tri12, Trisomy 12; U-CLL, IGHV-unmutated CLL.
Research
© 2018 by The American Society for Biochemistry and Molecular Biology, Inc.
This paper is available on line at http://www.mcponline.org
los
776 Molecular & Cellular Proteomics 17.4
 by guest on Septem
ber 20, 2018
http://w
w
w
.m
cponline.org/
D
ow
nloaded from
 
pathogenesis (5, 6). More recently, the DNA methylation pro-
file of CLL cases was shown to closely reflect that of the
proposed cell of origin, namely memory B-cells (MBC) and
naive B cells (NBC) for M-CLL and U-CLL, respectively. Inter-
estingly, both studies identified a third epigenetic CLL sub-
group with an intermediate methylation signature enriched
within M-CLL with between 95 and 98% IGHV somatic mu-
tations. These three CLL epitypes exhibit different clinico-
biological features, with the MBC-like CLL cases exhibiting a
more indolent clinical course (7–10).
Although no single aberration appears to drive disease
development, many recurring gene mutations and chromo-
some abnormalities have been described in CLL, and several
have prognostic and/or predictive significance. Deletion of
17p and 11q which results in the loss of TP53, baculoviral IAP
repeat-containing 3 (BIRC3) or ataxia-telangiectasia mutated
serine/threonine kinase (ATM) respectively, are frequently as-
sociated with TP53 and ATM mutations on the remaining
allele and poor outcome following chemo-immunotherapy
(11, 12). In contrast the most frequent cytogenetic abnormal-
ity in CLL, deletion of 13q, results in increased expression of
the anti-apoptotic protein Bcl-2, largely because of loss of
miRNA15 and miR16–1, and is associated with a good prog-
nosis, particularly in M-CLL.
Other recurrent mutations also influence disease progres-
sion and treatment response. Next generation sequencing
studies have confirmed that mutations of splicing factor 3B
subunit 1 (SF3B1) (13) and neurogenic locus notch homolog
protein 1 (NOTCH1), a transmembrane receptor and tran-
scriptional regulator determining cell fate (14), are the most
frequent recurring mutations in CLL, with an incidence of
18% and 12%, respectively, at the time of initial treat-
ment. Mutations in either gene are associated with a poorer
outcome following chemo or chemo-immunotherapy and
NOTCH1 mutations are also predictive of a poor response
to chemotherapy plus anti-CD20 antibody combinations
(15, 16).
SF3B1 is a spliceosome component with a role in the
regulation of pre-mRNA intron excision. Heterozygous mis-
sense mutations of the C-terminal HEAT domain are the most
frequent alteration to SF3B1, impacting spliceosomal function
(17). Indeed, SF3B1 mutation has been shown to induce
large numbers of aberrantly spliced and altered gene prod-
ucts in CLL (18). The frequency of SF3B1 mutations and the
resulting changes to spliceosomal activity suggest that dys-
regulation of the spliceosome plays a prominent role in CLL
pathogenesis.
Liquid chromatography with mass spectrometry (LC-MS)
proteomics provides an effective means of establishing global
differential protein expression profiles. Several studies have
previously employed MS proteomics in the analysis of CLL
(recently reviewed (19, 20)); with the latest, a characterization
of 9 U-CLL versus 9 M-CLL, identifying 3521 and relatively
profiling 2024 proteins, of which 100 proteins were differ-
entially expressed (1.5-fold change, p  0.05) (21). Several
earlier studies provided limited proteome coverage but sug-
gested a number of markers of poor prognosis, such as
nucleophosmin, PDCD4 and TCL1 (22–27). Technological and
methodological advances such as Orbitrap technology, iso-
baric labeling and two dimensional chromatography have
greatly improved proteomics coverage, leading to the first
comprehensive drafts of the human proteome (28–30).
Our current discovery-stage study has applied isobaric la-
bels and LC-MS proteomics to the characterization of isolated
B-cell material from 3 healthy donors and 14 CLL patients.
CLL samples were selected to include a range of clinically
relevant CLL subtypes associated with poor prognosis versus
healthy donor B-cells with the aim of assessing CLL-specific
differential protein expression. The resulting quantitative
proteomes identified a strong signature common to CLL,
highlighting several potential therapeutic targets and suggest-
ing mechanisms, such as spliceosome overexpression, con-
tributing to pathogenesis.
MATERIALS AND METHODS
Materials—SDS, HPLC and LC-MS grade ACN and formic acid
(FA), methyl methanethiosulfonate (MMTS), tris(2-carboxyethyl)phos-
phine (TCEP), triethylammonium bicarbonate (TEAB), DMSO, hydrox-
ylamine were purchased from Sigma, St. Louis, Missouri. EasySep
human B-cell enrichment kits without CD43 depletion were pur-
chased from Stem Cell Technologies, Cambridge, UK. Tandem mass
tags (TMT) 10-plex isobaric labeling reagents and 100 l C18 solid
phase extraction tips were purchased from Thermo Scientific, Wal-
tham, MA. Proteomics grade trypsin was purchased from Roche,
Basel, Switzerland. Fetal calf serum (FCS) was purchased from
Lonza, Basel, Switzerland, lymphoprep medium from Axis-Shield Di-
agnostics, Dundee, UK, and anti-human antibodies against CD3
(OKT3) and CD19 (HIB19) from Biolegend, San Diego, CA.
Isolation of Healthy Donor and CLL B-cells From Clinical Sam-
ples—Ethical approval for the use of human samples was granted
under REC references 228/02/t (Southampton) and 06/Q2202/30
(Bournemouth). Peripheral blood mononuclear cells (PBMCs) were
derived from healthy donors and CLL patients by Southampton Blood
Services or Bournemouth Tissue Bank, respectively. PBMCs were
isolated from whole blood or blood cones by density gradient centri-
fugation as previously described (3). PBMCs were frozen at 5  107
cells/ml in FCS containing 10% v/v DMSO. Healthy donor and CLL
patient PBMCs were defrosted, washed and B-cells isolated by neg-
ative selection using the EasySep human B-cell enrichment kit with-
out CD43 depletion, according to the manufacturer’s instructions.
The enriched B-cells were washed 3 times in excess PBS. B-cell
purity was assessed by immunostaining with CD19 and CD3 by flow
cytometry and yielded at least 90% purity in all samples (supplemen-
tal Table S1). Isolated cell pellets were snap frozen and stored in liquid
nitrogen before lysate preparation.
Experimental Design and Statistical Rationale—CLL samples were
selected to include a range of clinically relevant CLL subtypes asso-
ciated with poor prognosis. Samples were assigned evenly across
two batches of analyzed samples, to accommodate the capacity
limits of the isobaric labels (supplemental Table S1). To simultane-
ously analyze and provide relative quantitative comparability of 14
CLL proteomes, samples were assigned to two tandem mass tag
(TMT) 10-plex label sets. Three healthy donor B-cell (HDB) samples
were used as both biological and inter-experimental bridging con-
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trols. HDB peptides were prepared and TMT-labeled before bifurca-
tion and allocation to each 10-plex. The selected samples included
(non-discretely) 5 Trisomy 12 cases, 3 CD38 (99%) cases, 8 un-
mutated IGHV cases, 5 NOTCH1-mutant cases and 5 SF3B1-mutant
cases (supplemental Table S1).
To minimize batch effects, reduce technical noise and disregard
inconsistent observations, a stringent approach considering only the
smallest of the CLL to HDB fold changes was adopted; detailed in
Quantitative and Statistical Analysis of MS Data below. CLL:HDB
ratios were evaluated by an FDR-corrected 1 sample t test and
compared alongside a value termed the regulation score (Rs) (31), a
more robust measure than an average, also detailed below. With 14
samples, in those instances where variation was as low as 25%, a fold
change of 1.25 could be concluded, based on the power analysis
calculations presented by Levin (33). Use of standard deviation as
the denominator in the regulation score adjusted for variation on a
case by case basis. At a threshold of Rs0.3, the lowest fold change
defined as significantly regulated was 1.25, observed with an average
variation of 18%.
Sample and Peptide Preparation and Labeling for LC-MS—Snap
frozen cell pellets were lysed on ice by trituration with a 23 gauge
needle in 0.5 M TEAB containing 0.05%w/v SDS. Disrupted cells were
further sonicated on ice and lysates cleared by centrifugation at
16,000 g for 10 min at 4 °C. Protein concentration was determined by
a Direct Detect Spectrometer (Millipore, Billerica, MA). One hundred
g of cell lysate (200 g for each HDB sample, for use across two
10-plex experiments) was reduced with 50 mM TCEP and alkylated
with 200 mM MMTS, before digestion overnight at RT with a 30:1 ratio
of proteomics grade trypsin. Peptides were incubated with TMT 10-
plex isobaric tags according to the manufacturer’s instructions. CLL
sample peptides were assigned to two TMT 10-plex label sets, A and
B, respectively, as follows: 128N A,B: 3999, 2886; 128C A,B: 2497,
2483; 129N A,B: 568, 625; 129C A,B: 653, 4140; 130N A,B: 3405,
1194; 130C A,B: 3156, 1125; 131 A,B: 4621, 2459. For the healthy
donors, all 200 g of B-cell peptides were labeled in the same
reaction with labels 126 AB, 127N AB and 127C AB for donors
1, 2 and 3, respectively. Peptides were lyophilized at RT by vacuum
concentration and reconstituted in 2% v/v ACN, 0.1% v/v FA and
pooled to their respective 10-plex A and 10-plex B, with half the
labeled material from each of the three HDBs being assigned to each
10-plex.
Peptide Prefractionation—Peptides were cleaned using three rep-
etitions of solid phase extraction using 100 l C18 zip tips according
to manufacturer’s instructions. Peptides were lyophilized and recon-
stituted in 2% v/v ACN, 0.1% v/v NH4OH, and resolved using high-pH
RP C8 chromatography (150 mm  3 mm ID x 3.5 m particle,
XBridge) (Waters, Milford, MA) at 300 l/min with a LC-20AD HPLC
system (Shimadzu, Kyoto, Japan) maintained at 30 °C, using the
mobile phases (MP); A - 99.9% H2O, 0.1% NH4OH, B - 99.9% ACN,
0.1% NH4OH. The 120 min gradient was as follows; 0 min; 2% B, 10
min; 2% B, 75 min; 30% B, 105 min; 85% B, 120 min; 2% B. Fractions
were collected in a peak-dependent manner and individually lyophi-
lized. The top 25 high-abundance peptide fractions—reproducibly
between both experiments—were selected for individual analysis and
the remaining fractions were orthogonally concatenated.
Peptide Fraction Analysis by LC-MS/MS—Lyophilized peptide
fractions were individually reconstituted in 2% ACN, 0.1% FA and
500 ng of peptides loaded by a Dionex Ultimate 3000 (Thermo
Scientific) and analyzed by LC-MS/MS, described previously (31). In
summary, peptides were trapped by C18 and eluted over a reverse
phase gradient of 8 h (the richest fraction), 5 h (2nd–4th richest), 4 h
(6th–13th richest), and 3 h (remaining and pooled). Gradients for each
group (8, 5, 4 and 3 h, respectively) were as follows: 2% (0 mins), 22%
(350, 200, 160, 110 mins), 45% (415, 250, 200, 145 mins), 85% (465,
285, 225, 165 mins) organic phase (94.9% ACN, 5% DMSO, 0.1% FA)
in aqueous phase (2% ACN, 5% DMSO, 0.1% FA). The total MS time
for each proteome was 210 h.
Peptides were analyzed with an LQT-Orbitrap Elite Velos Pro hy-
brid mass spectrometer (Thermo Scientific). MS analysis of eluting
peptides was conducted between 350 and 1900m/z at 120,000 mass
resolution. The top 12  2 and 3 precursor ions per MS scan
(minimum intensity 1000) were characterized by tandem MS with
high-energy collisional dissociation (HCD) (30,000 mass resolution,
1.2 Da isolation window, 40 keV normalized collision energy) and CID
(ion trap MS, 2 Da isolation window, 35 keV). Additionally, the DMSO
ion at 401.922718 (MS1) (32) and the TMT-H ion at 230.170422
(MS2) were used as lockmasses and the MS was calibrated weekly.
MS Data Processing—Target-decoy searching of raw spectra data
was performed with Proteome Discoverer software version 1.4.1.14
(Thermo Scientific). Spectra were subject to a two stage search, both
using SequestHT (version 1.1.1.11), with Percolator used to estimate
FDR with a threshold of q  0.01. In both searches, fragment ion
mass tolerances of 0.02 Da and 0.5 Da were used for HCD and CID
spectra, respectively. Fixed modifications of Methythio (C), TMT (K
and N terminus) were used, searching for tryptic peptides. The first
allowed only a single missed cleavage, minimum peptide length of 7,
precursor mass tolerance of 5 ppm, no variable modifications and
searched against the human UniProt Swissprot database (down-
loaded January 2015; 20,159 protein sequences). The second search
used only spectra with q  0.01 from the first search, allowed 2
missed cleavages, minimum peptide length of 6, searched against the
human UniProt trembl database (downloaded 01/15, 67,812 protein
sequences), precursor mass tolerance of 10 ppm and a maximum of
2 variable (1 equal) modifications of; TMT (Y), oxidation (M), deami-
dation (N,Q) or phospho (S,T,Y). PhosphoRS was used to predict the
probability of specific phosphorylated residues. Reporter ion intensi-
ties were extracted from non-redundant PSMs with a tolerance of 20
ppm. Data from the two 10-plex experiments was searched sepa-
rately and combined for protein grouping by Proteome Discoverer.
The raw data and processed outputs have been deposited to the
ProteomeXchange Consortium (33) via the PRIDE partner repository
with the dataset identifier (PXD002004).
Quantitative and Statistical Analysis of MS Data—Log2 (ratios) were
generated describing each CLL sample relative to the three HDB
bridging controls (supplemental Table S2). To select for only the most
robust and consistent findings, the ratio of CLL:HDB control was
assessed for all 3 HDB controls and, rather than a potentially misrep-
resentative average value, the ratio with the lowest fold change was
selected. Findings with both up and downregulation for a protein
among the 3 CLL:HDB ratios were rejected. For example: for fold-
changes of 1.4, 1.5 and 1.8, 1.4 was selected; for fold-changes of
2.2, 1.7, 1.9 - 1.7 was selected; for fold-changes of 1.5,
1.9, 1.3 - a value of 0 was taken.
To reduce ratio compression, peptide spectrum match data for
proteins (q0.01) were exported from Proteome Discoverer and sub-
mitted to Statistical Processing for Isobaric Quantitation Evaluation
(SPIQuE) at spiquetool.com. This method weighted the contributions
of each PSM quantitation to a protein’s quantitation based on PSM
features (manuscript in preparation). For example, high-intensity pep-
tides with low isolation interference were given a greater weighting
factor, as previously applied (31).
Because of the substantial differences in non-B-cells present in the
HD and CLL PBMCs, contamination emerged in the HDB samples as
a number of downregulated proteins. To accommodate for the con-
tamination, the analyses primarily focused on proteins overex-
pressed, and therefore specifically attributable to CLL. As the most
apparent source of contamination in the proteomics results were
platelet-derived proteins, a filtering list consisting of the 1000 most
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abundant platelet proteins was generated from a prior proteomics
analysis of platelets, defined by copy number (described previously
(34)). Of these 1000 proteins, 194 were observed with apparent over-
expression in the HDB samples which were subsequently removed
from the dataset. Additionally, the WT CLL sample 4621 appeared as
an outlier and was therefore excluded from further analyses.
For the minimally deviated log2 (ratios), differential expression in
CLL, relative to HDB, was defined by an FDR-corrected one sample
t test, where p  0.05 and the regulation score (Rs), where Rs0.3 or
–0.3. Rs provided a single, robust measure, representative of both
the magnitude and consistency of differential expression (Rs	mean/
(standard deviation 1)). For proteins with no, or inconsistent differ-
ential expression, the Rs tended toward 0.
Bioinformatics Analyses—Proteins reaching the thresholds outlined
above were submitted to either Ingenuity Pathway Analysis (IPA) or
Database for Annotation, Visualization and Integrated Discovery (DA-
VID). For DAVID analyses, the default settings were used for pathway
and gene ontology (GO) term enrichment, with Benjamini-corrected p
values of 0.05 considered significant. For IPA analyses, default
settings were used. Annotations of biomarkers and drug targets were
conducted by IPA. Hierarchical clustering was conducted using log2
(ratios) and Cluster 3.0 (University of Tokyo, Human Genome Centre)
clustering based upon Euclidian distance and complete linkage. Java
TreeView (version 1.1.6r2) was used to visualize the clustering. Chro-
mosome enrichment analysis was performed in DAVID, using default
setting and visualized using Ensembl geneome browser.
Flow Cytometry—Cells were stained with either the manufactu-
rer’s recommended concentration, or 10 g/ml, of in-house anti-
body for 30 min in the dark at 4 °C, washed and analyzed by flow
cytometry with a FACScalibur (BD Biosciences, Franklin Lakes, NJ)
(35, 36).
Western Blotting—Independent cohorts of isolated B-cells and
CLL cells were washed in cold PBS and lysed in RIPA buffer (150 mM
NaCl, 1% Triton X-100, 0.5% Deoxycholate, 0.1% SDS, 50 mM Tris,
pH 8). Protein content was quantified against a BSA standard curve
using a standard Bradford assay (BioRad, Hemel Hempstead, UK). 40
g protein was loaded into 10% Bolt Novex gels (Thermo Fisher) and
transferred to a methylcellulose membrane (GE Lifesciences, UK) by
standard techniques. Membranes were probed with anti-CKAP4 (G1/
296, 1:500 dilution, Enzo Life Sciences, Farmingdale, NY), anti-
INPP5F (H00022876-B01P, 1:500 dilution, Abnova, Taiwan), anti-
ROR1 (4102, 1:500 dilution, CST, Danvers, MA), anti-Wee1 (D10D2,
1:1000 dilution, CST), anti-Bcl-2 (610539, 1:500 dilution, BD Biosci-
ences), anti-CD79b (AT105–1, 2 g/ml, Produced in house).
RESULTS
Quantitative Proteomics of CLL Relative to Healthy Donor
B-cell Samples Identifies a Consistent, Reproducible CLL
Phenotype—The MS and TMT workflow applied to measure
relative differential expression in the proteomes of CLL cells
versus HDB controls is summarized in Fig. 1. A total of 8694
proteins were identified (q0.01) of which 5956 proteins
were relatively quantified for all samples (supplemental Ta-
ble S2).
Hierarchical clustering of differential expression across the
14 CLL samples, relative to HDB, highlighted a broad CLL-
specific signature with no distinctly clustered subtypes (Fig.
2A, 2B). The reproducibility of this signature was also appar-
ent when comparing the average CLL expression determined
in the two distinct 10-plex experiments (R2 	 0.799) and the
technical reproducibility between the HDB bridging controls
(R2 	 0.797) (supplemental Fig. S1).
544 significantly overexpressed and 592 significantly un-
derexpressed CLL proteins, relative to HDB, were identified
with a regulation score of 0.3 or -0.3, respectively (Fig.
2C). Among the overexpressed proteins were examples of
well-characterized hallmarks of CLL; CD5, BCL2, CD23 and
ROR1. Eighteen proteins were identified with a greater over-
expression than CD5, several of which were previously unde-
scribed in CLL (Fig. 2D).
In addition to the overexpression of CD5, BCL2, CD23 and
ROR1, several other previously reported CLL protein upregu-
lations were present in the data; including ST14/matriptase,
CD6, PTPN22, CDKN1B/p27, TRAF1, JUND, BMI1, IKZF3/
Aiolos, TOSO, DIABLO/SMAC and SIT1 (Fig. 3A). Additionally,
overexpression was also apparent, although more variably,
for ZAP-70 and IL4R.
Markers differentiating CLL subtypes were also observed
by proteomics. Integrin alpha 4 (CD49d) expression was sig-
nificantly higher in trisomy 12 cases as previously described
(37), IgM expression associated with U-CLL cases (3), CD38
expression was correctly identified as significantly higher in
CD38 (99%) cases, and the Y-chromosome-encoded pro-
teins (EIF1AY and RPS4Y1) allowed the differentiation of pa-
tient genders (supplemental Fig. S1). Subtype specific differ-
ences emerging from the proteomics were considered
(supplemental Fig. S3, Table S3), however lacked the statis-
tical power for significant findings.
Putative Novel CLL Immunophenotypes and Drug Tar-
gets—In addition to confirmation of established characteris-
tics, several novel observations emerged among the most
upregulated proteins (Fig. 2C, 2D). Cytoskeleton-associated
protein 4 (CKAP4), a cell surface receptor for antiproliferative
factor (APF), was the most significantly and consistently up-
regulated CLL protein (250–590% HDB expression, p	 1.8
108) with 34 unique peptides identified from over 500 PSMs
and has not previously been reported in CLL at the protein
level. At the mRNA level, no overexpression was detected
(supplemental Fig. S2) (38). To validate this finding, Western
blotting was employed, evaluating CKAP4 expression in the
proteomics-analyzed samples and an independent cohort of
10 additional CLL samples, relative to HDB controls (Fig. 3B,
3C). CKAP4 was observed to be substantially overexpressed
in all but two CLL samples, with little CKAP4 expression
observed in healthy B-cells.
INPP5F (SAC2), an inositol 4-phosphatase with a role in
AKT signaling, was also found to be among the top 20 over-
expressed CLL proteins (200–500% HDB expression in 12/14
samples, p 	 1.2  105). Western blot validation (Fig. 3B,
3C) confirmed this overexpression, but appeared more vari-
able in the independent cohort than observed by proteomics.
The G2 checkpoint kinase, Wee1 was observed with signifi-
cant overexpression in CLL (175% HDB expression in 9/14
samples, p 	 4.3  105). Annotation by IPA highlighted
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Wee1 as a potential therapeutic target of the inhibitor
MK1775. Again, overexpression was confirmed by Western
blotting with the majority of CLL samples having greater Wee1
expression than HDB samples. BCL2, ROR1 and CD79b ex-
pression were also evaluated to demonstrate the concord-
ance between the proteomics- and Western blotting- derived
ratios for proteins with known over- or under-expression in
CLL.
In addition to the proposed cell surface expression of
CKAP4, CLL proteomics identified 20 consistently upregulated
proteins annotated with surface localization (Fig. 4). This list
highlighted 10 putative novel markers, CKAP4, PIGR, LAX1,
CLEC17A, ATP2B4, TMCC3, ST6GAL1, ATP1B1, C17orf80,
and NPTN (supplemental Fig. S4), with no previous descriptions
of protein upregulation in CLL, providing them as targets for
future evaluation for roles in CLL biology or as bio-markers.
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patient PBMCs
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isolation
PBMCs
Non-B-cells
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Healthy donor
B-cells (HDB)
Whole cell lysates
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FIG. 1. CLL proteomics workflow. PBMCs from 14 CLL patients and 3 healthy donors were subjected to negative B-cell isolation followed
by whole cell lysis, reduction, alkylation and trypsin digestion. 100 g of peptides from each CLL sample was assigned to one of two
tandem mass tag (TMT)-labeled 10-plex experiments. 200 g of each healthy donor B-cell (HDB) protein lysate was labeled and bifurcated
to provide bridging controls across the two 10-plex experiments. Each 10-plex was handled and analyzed separately using 2-dimensional
liquid chromatography coupled with data-dependent mass spectrometry; in each case, 60 peak-dependent fractions were analyzed.
Peptides were identified from mass spectra using target-decoy searching (false discovery rate of 1%). The identified proteins were
quantitated from isobaric labels relative to HDB bridging controls and differential expression analyzed to identify CLL-specific differences
in protein expression.
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FIG. 2. Quantitative proteomics profiles and characteristics of CLL samples. A, Summary of the major characteristics of the 14 CLL
samples, including; the assigned TMT 10-plex experiment (A or B), patient gender, presence of mutations to either NOTCH1 or SF3B1 genes,
IGHV mutation status (U-IGHV, solid fill; unmutated IGHV, open), trisomy 12 status (Tri12), CD38 (99%) cases. B, Hierarchical clustering
of 5956 protein log2 (ratios) for the 14 CLL samples relative to HDB, sorted by regulation score. C, Volcano plot demonstrating proteins
observed with significant overexpression (Rs0.3, p  0.05) or underexpression (Rs-0.3, p  0.05) in CLL versus HDB. A selection of the
most overexpressed proteins are annotated, identifying the accepted CLL-specific hallmarks BCL2, ROR1 and CD5. D, The top 20 most
consistently overexpressed proteins in CLL identified by the proteomics.
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FIG. 3. Validation of proteins deemed overexpressed by CLL proteomics. A, Proteomics-derived quantitations for proteins previously
described with overexpression in CLL, relative to HDB controls. B, Western blot validation of differential protein expression observed in an
independent cohort of CLL samples versus HDB controls. C, Comparison between the differential expressions observed for key proteins by
Western blotting and proteomics for CLL and HDB controls.
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Although for CKAP4, and to some extent PIGR, sur-
face localization may be affected by internalisation, other
candidates, such as lymphocyte transmembrane adapter 1
(LAX1), transmembrane calcium-transporting ATPase (ATP2B4)
and prolectin (CLEC17A) are likely primarily localized
to the cell periphery. LAX1, ATP2B4, and CLEC17A may
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FIG. 4. Proteomics identification of CLL-overexpressed cell surface proteins. Proteomics-derived quantitations for the 20 most
consistently upregulated cell surface-expressed proteins in CLL, relative to HDB. The data represent the number of unique peptides and PSMs,
the Log2 (ratios) relative to HDB, average Log2 (ratios) and proposed function and evidence for prior observations in CLL.
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additionally present potential effectors of BCR signaling
(39–42).
Next, overexpressed CLL proteins were annotated for their
potential as therapeutic targets based on existing drug/inhib-
itor knowledge using IPA (Fig. 5). Both functional heme oxy-
genase isoforms (HMOX1 and HMOX2), which offer cytopro-
tective effects through free heme degradation, were observed
upregulated and annotated as targets of tin mesoporphyrin.
Histone deacetylases HDAC3 and HDAC7, and to a lesser
extent HDAC1 and sirtuin 5, also presented putative targets of
inhibition. This list additionally contained several kinases as
therapeutic targets, such as two mitogen-activated protein
kinases, MAPK8/JNK1 and MAPK13; two tyrosine-protein ki-
nase proto-oncoproteins, FGR and LCK; and two cell cycle
progression kinases, cyclin-dependent kinase 7 (CDK7) and
the G2 checkpoint kinase WEE1.
mRNA Processing Upregulation in CLL—Gene ontology
(GO) term enrichment was used to identify over-represented
features of CLL biology (Fig. 6A). Transcription and transcript
processing were dominant features among the 544 overex-
pressed proteins, with “mRNA processing” the most signifi-
cantly enriched term (p 	 2.9  1048) with 95 annotated
proteins. Most of the most significant biological process
terms additionally described mRNA-related processes. Four
terms describing RNA splicing, for instance, were highly en-
riched (n72 proteins, p  1040). Another emerging trend
was that of chromatin modification and organization (n84,
p  2.3  1023). Enrichment of cellular component and
molecular function terms further described the dysregulation
of mRNA-related processes, such as “nucleoplasm” (n	 258,
p 	 2.1  1069), “spliceosomal complex” (n 	 44, p 	 2.0 
1026) and “RNA binding” (n 	 167, p 	 6.0  1045). IPA
canonical pathway enrichment identified broad upregulation
of proteins and isoforms involved in “cleavage and poly-
adenylation of pre-mRNA” (p 	 2.0  1010) (Fig. 6B) and
“preinitiation complex assembly” (p 	 1.7  104) (Fig. 6C).
Upregulated KEGG pathways were also interrogated, iden-
tifying a 9-fold enrichment of spliceosome components (n 	
36, p 	 1.3  1021) (Fig. 7A). A further 60 components were
identified with marginal upregulation (0.1Rs0.3, p  0.05).
Fig. 7B presents all proteins within the quantified proteome
which map to the KEGG spliceosome pathways, highlighting
a near-consistent trend of some degree of over-expression
across the CLL samples relative to HDB.
DISCUSSION
CLL has been the subject of numerous investigations ap-
plying genomics and transcriptomics that have contributed
greatly to the clinical and biological understanding of the
disease (6, 43–45). However, low correlations observed be-
tween mRNA and protein expression limits insight from these
studies (46, 47). Indeed, a comparison between a previous
transcriptomics analysis of CLL (38) and these proteomics
results highlight minimally correlated differential expression
(supplemental Fig. S2). Proteomics has been applied to CLL
in several investigations providing insight into potential differ-
ences between subtypes and some CLL-specific signatures
(21, 22, 25, 26, 48, 49). To date, however, CLL proteomics
studies have lacked sufficient coverage to identify most ex-
pressed proteins and are yet to fully explore comparisons with
healthy donor B-cell controls.
This study aimed to implement advances in quantitative
LC-MS proteomics to provide a detailed characterization of a
broad spectrum of CLL samples and evaluate changes in
protein expression relative to B-cells derived from healthy
donors. Overall, this investigation provided a substantial, re-
producible (supplemental Fig. S1) and representative (Fig. 3)
description of the CLL proteome to a depth of almost 6000
proteins. Additionally, the accuracy of the results for individual
samples was highlighted by the expression of key subtype
markers (supplemental Fig. S1) suggesting the potential of the
presented methods for the dissection of subtype-specific dif-
ferences in CLL and other cancers in the future.
The most striking finding was that of a consistent subtype-
independent expression profile across the CLL samples (Fig.
2B). Given the heterogeneous clinical nature of CLL, some
variation and clustering of subtypes was anticipated, although
homogeneity among CLL subtypes has also been observed
previously by transcriptomics (5, 6). This suggests that the
phenotypic differences between CLL subtypes may either be
a product of post-translational modifications, microenviron-
ment interactions or CLL niche-specific characteristics. Fur-
ther studies with greater sample numbers will be required to
better understand these potentially subtle differences in pro-
tein expression.
Phenotypic differences exist between CLL cells in lymph
nodes and peripheral blood (50), suggesting that evaluation of
CLL cells from additional niches may be required to under-
stand the differences in disease behaviors observed between
subtypes. Furthermore, evaluation of fractionated B-cell sub-
sets from several niches would serve as more informative
controls. Indeed, given recent insights from methylation stud-
ies relating to the likely cell of origin for different CLL sub-
types, B-cell subsets relevant to each CLL sample (i.e. MBC
for M-CLL and NBC for U-CLL) should be evaluated, guided
by their CpG methylation signatures (7–10). Currently, we are
not aware of proteomics data describing these B-cell subsets.
The findings presented here provide several potential novel
hypotheses for further investigation. CKAP4, for instance (Fig.
2D, 3), was robustly identified as a highly abundant, overex-
pressed, putative surface protein in CLL and validated in a
separate cohort by Western blotting. This offers potential
mechanistic insight into CLL and presents a prospective clin-
ical tool. In addition to roles in the endoplasmic reticulum and
as a transcription factor (51), CKAP4, also known as CLIMP-
63, can act as a cell surface receptor for tissue plasminogen
activator (tPA) (52), surfactant protein A (SP-A) (53) and anti-
proliferative factor (APF) (54). APF treatment of a bladder
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FIG. 5. Proteomics identification of CLL-overexpressed drug targets. Proteomics-derived quantitations for the 20 most consistently upregu-
lated annotated targets of small molecular inhibitors in CLL, relative to HDB. Proteins were annotated using IPA. The data represent the number
of unique peptides and PSMs, the Log2 (ratios) relative to HDB, average Log2 (ratios) and IPA-annotated drugs known to target each protein.
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cancer cell line resulted in reduced proliferation, attributable
to substantially reduced phosphorylation of AKT and GSK3
and an increased expression of p53 (55). Interestingly,
substantial CKAP4 overexpression was also observed in
tumors of the E-TCL1 mouse model of CLL suggesting a
potential means of investigation (31). Targeting CKAP4 with
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FIG. 6. Bioinformatics analysis of the CLL-overexpressed proteome. A, GO term enrichment for the 544 overexpressed proteins (Rs0.3,
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either ligands or immunotherapy may offer means of treat-
ing CLL.
INPP5F mRNA overexpression in CLL has previously been
linked with low progression-free survival for patients under-
going fludarabine-based therapy (56). The proteomics and
Western blot validation presented here indicate that the
INPP5F protein is commonly overexpressed in CLL. Together
these observations suggest INPP5F may present a therapeu-
tic target in CLL, especially in treatment-resistant cases and
its mechanism in CLL warrants further investigation.
The identification of several consistently upregulated mem-
brane proteins in CLL versus HDBs (Fig. 4, supplemental Fig.
S4) highlighted the potential of proteomics approaches to
identify novel immunotherapy targets for selective targeting
with monoclonal antibodies. Additionally, identification of pro-
teins linked with BCR signaling should enable a better under-
standing of this process in CLL which may enable improved
therapeutic targeting of this currently incurable disease (39–
42). LAX1 was shown to be phosphorylated upon BCR stim-
ulation by Src and Syk (39), with B-cell hyper-responsiveness
observed in LAX1/ mice suggesting a regulatory role in
BCR signaling (57). ATP2B4 has a role in BCR-induced cal-
cium efflux (40) and Prolectin, also known as CLEC17A, is
expressed in germinal center B-cells where expression cor-
relates with proliferation (58). Prolectin also has a potential
role in BCR signaling, through an association with BLNK (42).
The analysis of drug targets further highlighted the potential
of proteomics in the identification of putative clinical tools
(Fig. 5). Wee1 overexpression, for instance (Fig. 3B), suggests
a potential target to inhibit the cell cycle, with the inhibitor
MK1775 shown to have therapeutic benefit in other cancers
(59). The upregulation of HMOX1 and 2 suggested an in-
creased degradation of free heme in CLL, combined inhibition
of which could induce apoptosis (60). A trend of HDACs
upregulated in these results highlighted the potential of tar-
geted HDAC inhibitors (HDACi). HDAC1 and HDAC3 were
both observed upregulated and specifically targetable, for
instance, with Entinostat; previously identified to induce pro-
apoptotic effects in CLL cells (61). HDAC7 additionally exhib-
ited consistent upregulation, observed previously at the
mRNA level (62), suggesting the possibility of more targeted
means of HDAC interference, with fewer off-target effects
compared with those seen in previous pan-HDACi trials in
CLL (62–64).
The strong signature of upregulated mRNA processes high-
lighted by the bioinformatics analyses (Fig. 6) suggests a
general underlying defect in CLL, independent of subtype.
SF3B1 mutations (65) and observations of major dysregula-
tion of splicing patterns (44) have previously indicated aber-
rant spliceosome activity in CLL. Additionally, inhibition of
SF3B1 by spliceostatin-A was toxic to CLL, independent of
SF3B1 mutational status, suggesting a broader role for aber-
rant splicing in CLL biology (66). The observation of broadly
consistent overexpression of spliceosomal proteins (Fig. 7)
may therefore offer some explanation for these previous ob-
servations. This reinforces the notion that interference with
aberrant splicing activity could offer a means of better under-
standing and potentially treating CLL.
A limitation to our study was the observation of non-B-cell
contaminants in the HDB samples resulting from the substantial
difference in percentage of non-B-cells and platelets between
healthy donor and CLL patient PBMCs; varying from 95% in
healthy PBMCs to below 10% in CLL patient PBMCs. Emphasis
was therefore placed upon overexpressed proteins in CLL and
conclusions based upon downregulated proteins - potentially
attributable to contamination in the HDB samples - were
avoided.
In summary, these results offer the first comprehensive
insight into the molecular composition of CLL compared with
healthy donor B-cells at the proteome level. They demon-
strate the potential of proteomics to identify protein-specific
differences between cancers and healthy tissues. The appli-
cation of such approaches on a larger scale promises the
elucidation of putative therapeutic targets and prognostic and
diagnostic indicators, in addition to the dissection of the
underlying cancer biology.
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